Halozyme Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Halozyme Therapeutics (HALO) Tops Q1 EPS by 1c
May 11, 2015 4:07 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.12), $0.01 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $18.7 million versus the consensus estimate of $19.4 million.
Halozyme Therapeutics sees FY2015 revenue of $85-95 million, versus the consensus of $93.3 million.
For earnings... More
